Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Bladé J.

J Clin Oncol. 2008 May 1;26(13):2171-7. doi: 10.1200/JCO.2007.14.1853. Epub 2008 Mar 24.

PMID:
18362366
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
[PubMed - indexed for MEDLINE]
3.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

PMID:
21411441
[PubMed - indexed for MEDLINE]
Free Article
4.

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.

von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A.

Eur J Haematol. 2008 Oct;81(4):247-52. doi: 10.1111/j.1600-0609.2008.01121.x. Epub 2008 Jul 10. Review.

PMID:
18637031
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.

Rajkumar SV.

Semin Hematol. 2003 Oct;40(4 Suppl 4):17-22. Review.

PMID:
15015892
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk